• Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Menu
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Search
Close

Conference 2022 Speaker Biography – Prof Elisa Llurba

Elisa L 2020 2

Elisa Llurba, MD, PhD (ELL) is the Head of Obstetrics and Gynecology Department at the Santa Creu i Sant Pau University Hospital. Associated Professor in Medicine of the Autonomous University of Barcelona (UAB) and principal investigator (PI) of the Perinatal and Women’s Health Group, in the Santa Creu and Sant Pau Hospital Research Institute in Barcelona. Coordinate’s work of 15 pre-doctoral researchers and 3 post- doctoral investigators. 

ELL presents an outstanding clinical research trajectory as leader and active member of a clinical and basic research group focused on the study of diseases derived placental insufficiency, preeclampsia, growth restriction and congenital heart disease.
ELL is the PI within the framework of RETICs 16/0022 entitled MATERNAL CHILD AND DEVELOPMENT NETWORK (SAMID) (Instituto de Salud Carlos III) in which is the coordinator of one of the two programs awarded in the last call for RETICs. From 2022 she is the Coordinator a RICORS network entitled “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain.

Her lines of research have also been funded by 4 public FIS calls last one in 2019 entittle: “Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: Clinical and experimental approach (FIS PI19/00702)” in line with previous financed projects as a PI: PI 16/00375 and PI13/01449, a non-commercial clinical trial (HOPPE-trial: EC-2010) and an IMPACT grant from the Department of Education and Science. The line has also been financed by private funds: PROGNOSIS ROCHE study. She is a co-investigator in Prenatal exposure to urban AIR pollution and pre- and post-natal Brain development (AIR-NB). IP: Jordi Sunyer. IRC H2020-SCI-2016-RDT-785994. 2018-2023. European Council. She is also PI in several international RCT in pregnancy: Hidroxicloroquin in pregnant covid women, covid -19 vaccination in pregnant women, heparin treatment, PROGNOSIS, among others.

She is part of the Editorial Board of Fetal Diagnosis and Therapy, BMC Pregnancy and Childbirth and European Journal of Nefrology. She has published more than 10 book chapters. Based on her achievements and contributions in her area of expertise she is an active collaborator as a reviewer of the Coordination and Evaluation Branch of the State Research Agency (AEI) and multiple peer review scientific journals. 

QUALITY INDICATORS OF SCIENTIFIC PRODUCTION: 

88 publications in international journals with 2731 citations  (H-index: 28; RG score: 34.46, 347 impact points, 5,5 average impact per publication), half of them published in the last four years being more than 76% of the articles in journals in the first quartile. The main contributions were: 

1) Provide evidence of the utility of angiogenic factors (AF) in patients at risk for preeclampsia: 1)Predictive value of sFlt1 / PlGF ratio in patients with clinical suspicion (N Engl J Med. 2016); 2) Study angiogenic markers in the management and clinical guidelines (FDT 2014, UOG 2016, 2015,2019); 3) Prediction of PE: Rheumatology 2019, UOG, 2018, 2016, 2013, 2008; Am J Reprod Immunol 2008, Hum Reprod 2012; Lupus, 2012; Am J Reprod Immunol 2012;. Immunobiology 2012); 3) Oxidative stress and placental angiogenic factors (Free Rad Biol Med 2004, Metabolism 2005, AJOG 2006, Hypertension in Pregnancy 2012, J Perinatal Medicine 2013); 4)Cardiovascular and neurological development: Nutrients 2020, JPM, 2013; UOG 2013 and 2008; Am J Reprod Immunol 2008, OBI, 2009) 5) Congenital Heart Disease and neurodevelopment: (UOG 2018, J Matern Fetal Neonatal Med 2016; Fetal Diagn Ther 2015; EHJ, 2013; UOG 2012). 6) Enviromental effects on maternal and fetal health. 

TRAINING: 

Specialist in Obstetrics and Gynaecology (2002), sub-specialization in Maternal- Fetal Medicine(2005), Doctor in Medicine in 2007 (European mention, excellent cum laude), 3 stages in prestigious foreign institutions (2001-2003-2011).
Master degree in Maternal-Fetal Medicine (2010), Master Degree in Health Management and Organizations (2018) 

MAIN AWARDS 

2013-2015: Member of “the National Children’s Study (NCS)-PERINATOLOGY WORKING GROUP of the: National Institute of Child Health and Human Development (NICHD), OMS. Obtaining grant for intensifying research in 2015-2016 from the Research Institute of Vall dHebron (VHIR).

2010: Grant for international fellowships (BAE-11/00071), Financed by the Department of Human Resources of Carlos III Institute of Health, Madrid, Spain 

2010: Research grant for a sojourn (2010 BE-DGR 00138) from AGAUR, Generalitat de Catalunya, for her post-doctoral training in the University of Maryland Medical Center. 

TEACHING ACTIVITY 

• Director of a Universitary Expert course from Barcelona University on Maternal and Obstetric Medicine from 2021.

• Director of a two-year Master Degree of Maternal-Fetal Medicine of the Autonomus University of Barcelona from 2017.

• Associated professor of the Autonomus University of Barcelona from 2013.

• Eight thesis defended between 2011-2021 and currently co-director of 12 doctoral thesis. 

 

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Have something to say about aspirin?

Contact Us Here
Footer Logo
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
TwitterLinkedin

Copyright © 2020 Aspirin Foundation

Website by mtc.

Have something to say about aspirin?

Please fill in the form below and we will contact you with further information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Pierre A Web Photo

    Pierre Amarenco

    Name

    Pierre Amarenco, MD, FAHA, FAAN

    Academic Affiliations:
    • Professor of Neurology at Paris-Diderot Sorbonne University 
    • Chairman of the Department of Neurology and Stroke Center; Bichat University Hospital
    • Co-Director INSERM Unit-698 “Clinical Research in Atherothrombosis”
    Discipline:

    Neurology and Vascular Neurology

    Scientific Interests:
    • Understanding and preventing stroke and vascular diseases
    • Clinical trials in prevention of vascular diseases
    • Carotid intima-media thickness studies
    • Lipid trials: prevention and therapeutic –protective- evaluation
    Declaration of Conflicts of Interest:

    N/A

    Return to Scientific Advisory Board
    CarloPatrono

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board

      Have something to say about aspirin?

      We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.